Physician profile
Roger A Klein
NPI 1689088379
$1,470.66
in general payments reported to CMS, 2019-2025
18 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $132 · 2021: $287 · 2022: $253 · 2023: $221 · 2024: $171 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $288.44 | 2019-2025 | |
| Amgen INC. | $171.56 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $126.70 | 2020-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $117.67 | 2019-2025 | |
| Lilly USA, LLC | $115.21 | 2020-2025 | Zepbound, Mounjaro |
| Organogenesis INC. | $88.99 | 2021-2023 | Puraply |
| Allergan, INC. | $68.28 | 2019-2020 | |
| Sanofi Pasteur INC. | $49.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.68 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.52 | 2024 | Rexulti |
| Dexcom, INC. | $16.79 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Merck Sharp & Dohme LLC | $15.19 | 2020 | |
| Exeltis, USA INC. | $13.97 | 2023 | Slynd |
| Janssen Pharmaceuticals, INC | $13.39 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $12.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.26 | 2022 | |
| Organon LLC | $10.97 | 2022-2025 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.